MedTrace Logo

Allogeneic HB-adMSCs vs Placebo for the Treatment of Acute Kidney Injury

NCT06654193 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2026-03-04

No results posted yet for this study

Summary

This study aims to investigate, through the collection of valid scientific evidence necessary to determine safety and effectiveness, the potential use of Allogeneic Hope Biosciences Adipose-derived Mesenchymal Stem Cells (HB-adMSCs) to prevent progression of trauma-induced Acute Kidney Injury (AKI).

Conditions

Interventions

DRUG

Allogeneic HB-adMSCs

Allogeneic HB-adMSCs

DRUG

Normal Saline

Sterile Saline Solution

Sponsors & Collaborators

  • The University of Texas Health Science Center, Houston

    collaborator OTHER

  • University of California, San Francisco

    collaborator OTHER

  • University of Alabama at Birmingham

    collaborator OTHER

  • Hope Biosciences LLC

    lead INDUSTRY

Principal Investigators

  • Charles S Cox, Jr., MD · The University of Texas Health Science Center, Houston

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-01
Primary Completion
2028-01-01
Completion
2028-01-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06654193 on ClinicalTrials.gov